AKVA group ASA hereby invites you to the presentation of the Q4 2025 financial results, which will take place as follows: Time: Friday February 13th, 2026, at 10:00 CET. Place: Hotel Continental in Oslo, Stortingsgaten 24/26.In addition to the physical presentation in Oslo, the event will be live streamed:https://qcnl.tv/p/royV7t2x9yGyqldQI0PCFg The presentation will be held in English and registration for the physical presentation can be submitted to abekkeheien@akvagroup.com Dated: 30 January 2026                        AKVA group ASA Web: www.akvagroup.com CONTACTS:Knut Nesse Chief Executive OfficerPhone: +47 51 77 85 00Mobile: +47 91 37 62 20E-mail: knesse@akvagroup.comRonny Meinkøhn Chief Financial OfficerPhone: +47 51 77 85 00Mobile: +47 98 20 67 76E-mail: rmeinkohn@akvagroup.com

Sampo plc, stock exchange release, 30 January 2026 at 8:30 am EET Sampo plc’s share buybacks 29 January 2026 On 29 January 2026, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  8,333 9.44 AQEU    79,549 9.44 CEUX  31,275 9.45 TQEX  91,646 9.44 XHELTOTAL 210,803 9.44  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November 2025,...

Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry population The company is finalizing the development plan for the optimal regulatory pathway to approvalAllschwil, Switzerland – January 30, 2026Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium™, taking place from February 2-6, 2026. The following two posters will be presented on February 5, 15:30 PST (February 6, 00:30 CET):Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study (#125, Kiosk 14-B) Lucerastat effect on kidney function in patients with...

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The offering is expected to close on February 2,...

VANCOUVER, British Columbia, Jan. 29, 2026 (GLOBE NEWSWIRE) — Anfield Energy Inc. (“Anfield” or the “Company”) (TSX.V: AEC; NASDAQ: AEC; FRANKFURT: 0AD) announces that it has entered into an amending and consent agreement (the “Amending Agreement”) with Extract Advisors LLC (“Extract”) to amend the terms of an existing credit facility (the “Credit Facility”) (see the Company’s news release dated October 6, 2023, April 17, 2024 and March 18, 2025) with Extract, as agent of the Credit Facility. Pursuant to the Amending Agreement, Extract consented to the Company’s proposed acquisition (the “Acquisition”) of all of the issued and outstanding securities of B.R.S. Inc. (see the Company’s news release dated December 18, 2025) (the “Consent”). In consideration for the Consent, the Company has agreed to issue 50,000 bonus common shares...

MONTREAL, Jan. 29, 2026 (GLOBE NEWSWIRE) — We have taken note of the post from the President of the United States to social media and are in contact with the Canadian government. Bombardier is an international company that employs more than 3,000 people in the U.S. across 9 major facilities, and creates thousands of U.S. jobs through 2,800 suppliers. Our aircraft, facilities and technicians are fully certified to FAA standards and renowned around the world. We are actively investing in expanding our U.S. operations, including a recent announcement in Fort Wayne, Indiana. Thousands of private and civilian jets built in Canada fly in the U.S. every day. We hope this is quickly resolved to avoid a significant impact to air traffic and the flying public. About Bombardier  At Bombardier (BBD-B.TO), we design, build, modify and maintain...

LONG BEACH, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today successfully launched its 81st Electron rocket and second launch in eight days to deploy a satellite for an Earth-observation constellation by the Korea Advanced Institute of Science and Technology (KAIST), Korea’s leading university dedicated to science and technology. ‘Bridging The Swarm’ lifted off on January 30th at 2:21 p.m. NZDT (01:21 UTC) from Rocket Lab’s private orbital launch site, Launch Complex 1 in New Zealand, to deploy the NEONSAT-1A satellite to a 540 km low Earth orbit. NEONSAT-1A is an advanced Earth observation satellite that will test the capabilities of the South Korean government’s future constellation of NEONSAT satellites...

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) — Kyivstar Group Ltd. (Nasdaq: KYIV; KYIVW) (“Kyivstar” or the “Company”), Ukraine’s leading digital operator, today announced the pricing of the public offering of 12,500,000 common shares (the “Offering”) by VEON Amsterdam B.V., the principal shareholder of the Company, and certain other selling shareholders (collectively, the “Selling Shareholders”) at a public offering price of USD 10.50 per share. The Company is not selling any common shares in the Offering. In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on February 2, 2026, subject to customary closing conditions. Morgan...

NEW YORK, New York, January 29, 2026 — VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or, together with its subsidiaries, the “VEON Group”) notes that Kyivstar Group Ltd. (Nasdaq: KYIV; KYIVW) (“Kyivstar” or the “Company”), Ukraine’s leading digital operator, today announced the pricing of the public offering of 12,100,000 common shares held by VEON Amsterdam B.V., the principal shareholder of the Company, and 400,000 common shares held by certain other selling shareholders (collectively, the “Selling Shareholders”) at a public offering price of USD 10.50 per share (the “Offering”). In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the public offering price, less underwriting discounts and commissions. Kyivstar...

New York, Jan. 29, 2026 (GLOBE NEWSWIRE) — M EVO GLOBAL ACQUISITION CORP II (the “Company”) announced today that it priced its initial public offering of 27,000,000 units at $10.00 per unit after upsizing the original offering of 22,500,000 units. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will trade under the ticker symbol “MEVOU” beginning January 30, 2026. Each unit consists of one Class A ordinary share of the Company, $0.0001 par value per share, and one-half of one redeemable warrant, each whole warrant entitling the holder to purchase one Class A ordinary share upon exercise, at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq under the symbols “MEVOX” and “MEVOW,”...